Genesis Therapeutics
1860 El Camino Real
Suite 400
Burlingame
CA
94010
United States
Tel: 8582205423
Website: http://www.genesistherapeutics.ai/
Email: nick@genesistherapeutics.ai
9 articles about Genesis Therapeutics
-
Genesis Therapeutics Closes Oversubscribed $200 Million Series B
8/21/2023
Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients with severe diseases, announced today that it has closed an oversubscribed $200 million round of Series B financing.
-
Genesis Therapeutics Announces Strategic Collaboration with Lilly to Discover Novel Therapies Using the Genesis Molecular AI Platform
5/3/2022
Genesis Therapeutics announced that it has entered into a strategic collaboration with Eli Lilly and Company to discover novel therapies for up to five targets across a range of therapeutic areas.
-
Genesis Therapeutics and Eli Lilly have entered into a strategic collaboration to discover novel therapies utilizing Genesis’ AI platform.
-
Genesis Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/11/2022
Genesis Therapeutics, a company pioneering AI technologies to create medicines for patients with severe and unmet medical needs, announced today that Evan Feinberg Ph.D., Genesis Therapeutics CEO and co-founder, will present at the 40th Annual J.P. Morgan Healthcare Conference.
-
Genesis Therapeutics Expands Executive Team with Addition of Will McCarthy as Chief Business Officer
4/28/2021
Genesis Therapeutics, a company pioneering AI technologies to create medicines for patients with severe and unmet medical needs, today announced the appointment of Will McCarthy as chief business officer.
-
With the expected Emergency Use Authorization (EUA) of Pfizer-BioNTech and Moderna’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Could it come from the field of neuroscience?
-
Genesis Therapeutics Secures $52M Series A to Further Accelerate AI Innovation and to Launch Drug Discovery & Development Pipeline
12/2/2020
Led by Rock Springs Capital with participation by funds and accounts advised by T. Rowe Price Associates, Inc., Andreessen Horowitz, and other major investors
-
Genesis Therapeutics Enters AI-driven, Multi-Target Drug Discovery Partnership with Genentech
10/19/2020
Genesis Therapeutics, a privately-held company inventing and deploying state-of-the-art artificial intelligence techniques to augment drug discovery and development, announced that it has entered into a multi-target collaboration agreement with Genentech, a member of the Roche Group.
-
In this multi-target partnership, Genentech will leverage Genesis’ Dynamic PotentialNet AI platform and other novel neural network algorithms.